Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
0.315
USD
|
-10.26%
|
|
-13.70%
|
-58.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29.95
|
38.2
|
28.31
|
19.54
|
7.858
|
4.977
|
-
|
-
|
Enterprise Value (EV)
1 |
29.95
|
38.2
|
28.31
|
19.54
|
7.858
|
4.977
|
4.977
|
4.977
|
P/E ratio
|
-3.02
x
|
-2
x
|
-2.13
x
|
-1.41
x
|
-0.96
x
|
-0.61
x
|
-0.71
x
|
-0.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.51
x
|
15.9
x
|
35.4
x
|
21.7
x
|
9.36
x
|
7.02
x
|
5.53
x
|
5.53
x
|
EV / Revenue
|
6.51
x
|
15.9
x
|
35.4
x
|
21.7
x
|
9.36
x
|
7.02
x
|
5.53
x
|
5.53
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-3,333,271
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,377
|
1,990
|
2,858
|
2,882
|
10,378
|
15,800
|
-
|
-
|
Reference price
2 |
21.75
|
19.20
|
9.904
|
6.780
|
0.7572
|
0.3150
|
0.3150
|
0.3150
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/31/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.6
|
2.4
|
0.8
|
0.9
|
0.8394
|
0.7085
|
0.9
|
0.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.54
|
-13.59
|
-13.14
|
-14.24
|
-7.698
|
-8.324
|
-9.07
|
-10.42
|
Operating Margin
|
-229.15%
|
-566.1%
|
-1,642.61%
|
-1,582.1%
|
-917.12%
|
-1,174.81%
|
-1,007.78%
|
-1,158.33%
|
Earnings before Tax (EBT)
1 |
-9.966
|
-18.53
|
-13.42
|
-14.95
|
-7.909
|
-8.4
|
-8.8
|
-9.3
|
Net income
1 |
-9.4
|
-17.7
|
-12.6
|
-13.8
|
-6.141
|
-8.576
|
-9.5
|
-10.86
|
Net margin
|
-204.35%
|
-737.5%
|
-1,575%
|
-1,533.33%
|
-731.6%
|
-1,210.44%
|
-1,055.56%
|
-1,206.11%
|
EPS
2 |
-7.200
|
-9.600
|
-4.650
|
-4.810
|
-0.7900
|
-0.5150
|
-0.4450
|
-0.4450
|
Free Cash Flow
|
-
|
-11.46
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-477.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/31/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.2514
|
0.2
|
0.4
|
0.1661
|
0.3172
|
0.3
|
0.2
|
0.1304
|
0.2448
|
0.1
|
0.2
|
0.2
|
0.2
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.522
|
-4.203
|
-3.395
|
-3.081
|
-3.57
|
-2.151
|
-1.63
|
-1.779
|
-2.138
|
-2.117
|
-2.005
|
-2.105
|
-2.105
|
-
|
-
|
Operating Margin
|
-1,798.9%
|
-2,101.32%
|
-848.82%
|
-1,854.6%
|
-1,125.61%
|
-716.9%
|
-815.16%
|
-1,363.89%
|
-873.28%
|
-2,117.09%
|
-1,002.5%
|
-1,052.5%
|
-1,052.5%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.704
|
-4.349
|
-3.542
|
-3.309
|
-3.754
|
-2.207
|
-1.612
|
-1.663
|
-2.426
|
-1.915
|
-2.1
|
-2.2
|
-2.2
|
-
|
-
|
Net income
1 |
-4.753
|
-4.3
|
-2.4
|
-3.309
|
-3.755
|
-1
|
-1.6
|
-1.663
|
-1.82
|
-1.9
|
-2.112
|
-2.212
|
-2.212
|
-
|
-
|
Net margin
|
-1,890.65%
|
-2,150%
|
-600%
|
-1,991.69%
|
-1,184.01%
|
-333.33%
|
-800%
|
-1,274.69%
|
-743.39%
|
-1,900%
|
-1,056.25%
|
-1,106.25%
|
-1,106.25%
|
-
|
-
|
EPS
2 |
-1.650
|
-1.500
|
-0.9000
|
-1.200
|
-1.240
|
-0.3600
|
-0.2200
|
-0.1600
|
-0.1600
|
-0.1800
|
-0.1100
|
-0.1200
|
-0.1200
|
-0.1100
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/13/22
|
8/12/22
|
11/10/22
|
3/31/23
|
5/15/23
|
8/21/23
|
11/13/23
|
3/15/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-11.5
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
0.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/31/23
|
3/15/24
|
-
|
-
|
-
|
Last Close Price
0.315
USD Average target price
2.5
USD Spread / Average Target +693.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -58.40% | 4.98M | | +11.60% | 106B | | -4.68% | 24.28B | | -0.61% | 21.96B | | -9.40% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|